Literature DB >> 15688287

Development and duration of human papillomavirus lesions, after initial infection.

Rachel L Winer1, Nancy B Kiviat, James P Hughes, Diane E Adam, Shu-Kuang Lee, Jane M Kuypers, Laura A Koutsky.   

Abstract

BACKGROUND: To determine the potential value of human papillomavirus (HPV) vaccines, information concerning the incidence and duration of clinically important lesions is needed.
METHODS: A total of 603 female university students were followed for a mean duration of 38.8 months. Triannual gynecologic examinations included cervical and vulvovaginal specimen collection for Pap and HPV DNA testing. Women with cytologic evidence of a high-grade squamous intraepithelial lesion (SIL) were referred for colposcopically directed biopsy.
RESULTS: Among women with incident HPV infection, the 36-month cumulative incidence of cervical SILs found by cytologic testing (47.2%; 95% confidence interval [CI], 38.9%-56.4%) was higher than that of vaginal SILs (28.8%; 95% CI, 21.3%-38.2%). The median time to clearance of cervical and vaginal SILs was 5.5 and 4.7 months, respectively. Among women with incident HPV-16 or HPV-18 infection, the 36-month cumulative incidence of cervical intraepithelial neoplasia (CIN) grade 2 was 20.0% (95% CI, 10.8%-35.1%), and that of CIN grade 3 was 6.7% (95% CI, 2.5%-17.0%). The 36-month cumulative incidence of clinically ascertained genital warts among women with incident HPV-6 or HPV-11 infection was 64.2% (95% CI, 50.7%-77.4%).
CONCLUSIONS: Intraepithelial lesions are common early events among women with incident HPV infection, and the interval between incident HPV-16 or HPV-18 infection and biopsy-confirmed CIN grade 2-3 appears to be relatively short.

Entities:  

Mesh:

Year:  2005        PMID: 15688287     DOI: 10.1086/427557

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  84 in total

1.  Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.

Authors:  Morgan A Marks; Philip E Castle; Mark Schiffman; Patti E Gravitt
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Risk factors for incident condyloma in a multinational cohort of men: the HIM study.

Authors:  Gabriella M Anic; Ji-Hyun Lee; Luisa L Villa; Eduardo Lazcano-Ponce; Christine Gage; Roberto José C Silva; Maria L Baggio; Manuel Quiterio; Jorge Salmerón; Mary R Papenfuss; Martha Abrahamsen; Heather Stockwell; Dana E Rollison; Yougui Wu; Anna R Giuliano
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

3.  Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women.

Authors:  Rachel L Winer; James P Hughes; Qinghua Feng; Long Fu Xi; Stephen Cherne; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-20       Impact factor: 4.254

4.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

5.  Human alpha-defensins block papillomavirus infection.

Authors:  Christopher B Buck; Patricia M Day; Cynthia D Thompson; Jacek Lubkowski; Wuyuan Lu; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 6.  Conservative management of adolescents with abnormal cytology and histology.

Authors:  Anna-Barbara Moscicki
Journal:  J Natl Compr Canc Netw       Date:  2008-01       Impact factor: 11.908

7.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 8.  Human papillomavirus disease and vaccines in adolescents.

Authors:  Anna-Barbara Moscicki
Journal:  Adolesc Med State Art Rev       Date:  2010-08

Review 9.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

10.  HPV16 E6*II gene expression in intraepithelial cervical lesions as an indicator of neoplastic grade: a pilot study.

Authors:  Dorota Pastuszak-Lewandoska; Anna Bartosińska-Dyc; Monika Migdalska-Sęk; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska; Krzysztof Szyłło; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2014-01-17       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.